REGULATED PRESS RELEASE published on 10/30/2023 at 06:00, 1 year ago Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil
PRESS RELEASE published on 10/27/2023 at 23:00, 1 year ago Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel
REGULATED PRESS RELEASE published on 10/27/2023 at 23:00, 1 year ago Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel
REGULATED PRESS RELEASE published on 10/23/2023 at 07:00, 1 year ago Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap
PRESS RELEASE published on 09/27/2023 at 23:15, 1 year 1 month ago Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations
PRESS RELEASE published on 09/25/2023 at 07:06, 1 year 1 month ago Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
PRESS RELEASE published on 09/19/2023 at 07:00, 1 year 2 months ago Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19
PRESS RELEASE published on 09/14/2023 at 07:00, 1 year 2 months ago Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
PRESS RELEASE published on 09/11/2023 at 07:00, 1 year 2 months ago Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia
PRESS RELEASE published on 09/04/2023 at 23:00, 1 year 2 months ago Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
Published on 11/22/2024 at 09:00, 4 hours 8 minutes ago Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 13 hours 8 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 15 hours 3 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 15 hours 18 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 16 hours 53 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/22/2024 at 11:54, 1 hour 14 minutes ago PIERER Mobility denies media reports about Mark Mateschitz's participation in PIERER Mobility and KTM
Published on 11/22/2024 at 11:45, 1 hour 23 minutes ago How 5G Transforms Life: A Foreigner's Journey Through East China's Digital Revolution
Published on 11/22/2024 at 11:21, 1 hour 47 minutes ago Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy
Published on 11/22/2024 at 11:06, 2 hours 2 minutes ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 06:58, 1 day 6 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 17 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 19 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 19 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 2 days 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
